Skip to content
sellModerate cluster of 510b5-1 plan

Neil Gregory Almstead sold $6.0M of PTCT

CHIEF TECHNICAL OPS OFFICER at PTC THERAPEUTICS, INC.. 71,928 shares at an average of $83.44, traded Nov 25, 2025, filed Nov 26, 2025.

Warning score
40
Value
$6.0M
71,928 shares
Holdings after
100,625
-70% from before
From 52-week low
+129%
low $36.19, close $82.93
From 52-week high
0%
high $82.93, as of Nov 25, 2025

Score components

  • Role
    Officer
    +15
  • Trade size
    $6.0M at market
    +25
  • Share of holdings sold
    Sold 70% of holdings
    +20
  • Cluster
    5 insiders selling within 14 days
    +15
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

PTCTOct 9, 2026 · close 64.70
Since filing Nov 26, 2025: -25.0%SPY +15.8% · excess -40.8%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001578850-25-000007, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Nov 25, 2025MOption exercise
Common Stock10b5-1
+2,475$18.01$45k103,100Nov 26, 2025
Nov 25, 2025SOpen-market sale
Common Stock10b5-1
-911$82.63$75k102,189Nov 26, 2025
Nov 25, 2025SOpen-market sale
Common Stock10b5-1
-990$83.44$83k101,199Nov 26, 2025
Nov 25, 2025SOpen-market sale
Common Stock10b5-1
-574$84.67$49k100,625Nov 26, 2025
Nov 25, 2025MOption exercise
Common Stock10b5-1
+2,020$33.02$67k102,645Nov 26, 2025
Nov 25, 2025SOpen-market sale
Common Stock10b5-1
-689$82.63$57k101,956Nov 26, 2025
Nov 25, 2025SOpen-market sale
Common Stock10b5-1
-862$83.35$72k101,094Nov 26, 2025
Nov 25, 2025SOpen-market sale
Common Stock10b5-1
-289$84.61$24k100,805Nov 26, 2025
Nov 25, 2025SOpen-market sale
Common Stock10b5-1
-180$85.17$15k100,625Nov 26, 2025
Nov 25, 2025MOption exercise
Common Stock10b5-1
+8,410$18.01$151k109,035Nov 26, 2025
Nov 25, 2025SOpen-market sale
Common Stock10b5-1
-2,790$82.82$231k106,245Nov 26, 2025
Nov 25, 2025SOpen-market sale
Common Stock10b5-1
-3,663$83.41$306k102,582Nov 26, 2025
Nov 25, 2025SOpen-market sale
Common Stock10b5-1
-1,757$84.56$149k100,825Nov 26, 2025
Nov 25, 2025SOpen-market sale
Common Stock10b5-1
-200$85.37$17k100,625Nov 26, 2025
Nov 25, 2025MOption exercise
Common Stock10b5-1
+47,624$33.02$1.6M148,249Nov 26, 2025
Nov 25, 2025SOpen-market sale
Common Stock10b5-1
-13,514$82.55$1.1M134,735Nov 26, 2025
Nov 25, 2025SOpen-market sale
Common Stock10b5-1
-21,844$83.33$1.8M112,891Nov 26, 2025
Nov 25, 2025SOpen-market sale
Common Stock10b5-1
-9,171$84.42$774k103,720Nov 26, 2025
Nov 25, 2025SOpen-market sale
Common Stock10b5-1
-3,095$85.15$264k100,625Nov 26, 2025
Nov 25, 2025MOption exercise
Common Stock10b5-1
+11,399$33.02$376k112,024Nov 26, 2025
Nov 25, 2025SOpen-market sale
Common Stock10b5-1
-3,744$82.61$309k108,280Nov 26, 2025
Nov 25, 2025SOpen-market sale
Common Stock10b5-1
-4,834$83.39$403k103,446Nov 26, 2025
Nov 25, 2025SOpen-market sale
Common Stock10b5-1
-2,621$84.54$222k100,825Nov 26, 2025
Nov 25, 2025SOpen-market sale
Common Stock10b5-1
-200$85.34$17k100,625Nov 26, 2025
Nov 25, 2025MOption exercise
Stock Option (Right to Buy)derivative10b5-1
-2,475$0.00$08,410Nov 26, 2025
Nov 25, 2025MOption exercise
Stock Option (Right to Buy)derivative10b5-1
-2,020$0.00$047,624Nov 26, 2025
Nov 25, 2025MOption exercise
Stock Option (Right to Buy)derivative10b5-1
-8,410$0.00$00Nov 26, 2025
Nov 25, 2025MOption exercise
Stock Option (Right to Buy)derivative10b5-1
-47,624$0.00$00Nov 26, 2025
Nov 25, 2025MOption exercise
Stock Option (Right to Buy)derivative10b5-1
-11,399$0.00$00Nov 26, 2025

Related signals

Other insiders at PTC THERAPEUTICS, INC. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
21Weak
PTCTsell 310b5-1
PTC THERAPEUTICS, INC.
Michael Schmertzler
director
$158k
2,500 shares
-0%
6Weak
PTCTsell 310b5-1
PTC THERAPEUTICS, INC.
Mark Elliott Boulding
EXEC. VP AND CLO
$133k
2,073 shares
-2%
27Weak
PTCTsell 310b5-1
PTC THERAPEUTICS, INC.
Glenn Steele Jr Md Phd
director
$782k
12,000 shares
-35%
28Weak
PTCTsell 210b5-1
PTC THERAPEUTICS, INC.
Michael Schmertzler
director
$1.3M
20,000 shares
-2%
20Weak
PTCTsell10b5-1
PTC THERAPEUTICS, INC.
Michael Schmertzler
director
$1.4M
20,000 shares
-1%
36Weak
PTCTsell 210b5-1
PTC THERAPEUTICS, INC.
Neil Gregory Almstead
CHIEF TECHNICAL OPS OFFICER
$253k
3,989 shares
-59%
15Weak
PTCTsell 210b5-1
PTC THERAPEUTICS, INC.
Mark Elliott Boulding
EXEC. VP AND CLO
$210k
3,019 shares
-3%
15Weak
PTCTsell 210b5-1
PTC THERAPEUTICS, INC.
Neil Gregory Almstead
CHIEF TECHNICAL OPS OFFICER
$216k
3,121 shares
-3%
4Weak
PTCTsell 210b5-1
PTC THERAPEUTICS, INC.
Mark Elliott Boulding
EXEC. VP AND CLO
$409k
5,894 shares
-5%
11Weak
PTCTsell 210b5-1
PTC THERAPEUTICS, INC.
Neil Gregory Almstead
CHIEF TECHNICAL OPS OFFICER
$72k
940 shares
-1%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.